Position in ALMS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$55,151,473
+$11,974,965 QoQ
Shares Held
1,959,896
0.0% QoQ
Ownership
1.51%
of shares outstanding
% of Portfolio
5.31%
of 13F equity value
Holder Rank
#20
of 196 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SR One Capital Management, LP holds $1,012,394,333 across 14 Biotechnology names. ALMS ranks #7 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MANE |
Veradermics, Inc
|
2,401,868 | $295,285,651 | |
| 2 | ZBIO |
Zenas BioPharma, Inc.
|
5,037,854 | $127,860,734 | |
| 3 | CRSP |
CRISPR Therapeutics AG
|
2,038,763 | $111,194,134 | |
| 4 | AVLN |
Avalyn Pharma Inc.
|
3,308,649 | $108,920,725 | |
| 5 | DSGN |
Design Therapeutics, Inc.
|
6,526,476 | $94,438,107 | |
| 6 | ODTX |
Odyssey Therapeutics, Inc.
|
3,794,883 | $71,002,260 | |
| 7 | ALMS |
Alumis Inc.
This page
|
1,959,896 | $55,151,473 | |
| 8 | ORIC |
Oric Pharmaceuticals, Inc.
|
4,615,384 | $49,984,608 |
All Filings in ALMS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $55,151,473 | 1,959,896 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $43,176,508 | 1,959,896 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $19,128,584 | 1,959,896 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $7,819,985 | 1,959,896 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $5,879,688 | 1,959,896 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $12,033,761 | 1,959,896 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $15,404,782 | 1,959,896 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $20,931,689 | 1,959,896 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $26,066,616 | 1,959,896 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||